التفاصيل البيبلوغرافية
| العنوان: |
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. |
| المؤلفون: |
Jones, Robin L., Chawla, Sant P., Attia, Steven, Schöffski, Patrick, Gelderblom, Hans, Chmielowski, Bartosz, Le Cesne, Axel, Van Tine, Brian A., Trent, Jonathan C., Patel, Shreyaskumar, Wagner, Andrew J., Chugh, Rashmi, Heyburn, John W., Weil, Susan C., Wang, Wenquan, Viele, Kert, Maki, Robert G. |
| المصدر: |
Cancer (0008543X); Jul2019, Vol. 125 Issue 14, p2445-2454, 10p |
| مصطلحات موضوعية: |
SARCOMA, DOCETAXEL, THERAPEUTICS, HEMATOPOIESIS, TUMOR markers, THERAPEUTIC use of antimetabolites, THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, RESEARCH, RESEARCH methodology, ANTINEOPLASTIC agents, DEOXYCYTIDINE, MONOCLONAL antibodies, EVALUATION research, MEDICAL cooperation, ANTIMETABOLITES, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, RESEARCH funding, TUMOR antigens, STATISTICAL sampling, LONGITUDINAL method, ANTIGENS |
| مستخلص: |
Background: Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM-1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma.Methods: Part 1 was an open-label, dose-finding, safety lead-in: 4, 6, or 8 mg/kg with gemcitabine and docetaxel (G/D; 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8). In part 2, patients were randomized in a double-blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological cohorts.Results: In part 2 with 209 patients, no significant difference in progression-free survival between ontuxizumab plus G/D (4.3 months; 95% confidence interval [CI], 2.7-6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6-8.3 months) was observed (P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77-1.49). Similarly, there was no significant difference in median overall survival between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2-21.1 months) and 21.1 months for the placebo plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82-1.82). No significant differences between the treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally well tolerated.Conclusions: Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft-tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer (0008543X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder